Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2019-11-15

FDA Approved: BASAGLAR KWIKPEN — Supplemental Application (Eli Lilly and Company)

View source ↗

Summary

The FDA approved a supplemental application for BASAGLAR KWIKPEN (insulin glargine) from Eli Lilly and Company.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • BASAGLAR KWIKPEN (Insulin glargine)

Snippet

SUPPL AP for BASAGLAR KWIKPEN (INSULIN GLARGINE)